m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG00756)
| Name |
Nitric oxide
|
||||
|---|---|---|---|---|---|
| Synonyms |
HNO; ()NO; 10102-43-9; AC1L3QHF; Bioxyde d'azote; Bioxyde d'azote [French]; CHEBI:16480; CHEMBL1200689; CTK0H7679; DTXSID1020938; EDRF; Endogenous Nitrate Vasodilator; Endothelium-Derived Nitric Oxide; Endothelium-derived relaxing factor (EDRF); INOmax; INOmax (TN); Mononitrogen monoxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxido de nitrogeno; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric Oxide, Endothelium-Derived; Nitric oxide; Nitric oxide (JAN); Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitric oxide, 985%; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen monoxide; Nitrogen oxide (NO); Nitrogen(II) oxide; Nitrosoradical; Nitrosyl; Nitrosyl hydride; Nitrosyl hydride ((NO)H); Nitrosyl radical; Nitroxide radical; Nitroxyl; OHM 11771; Oxide, Nitric; Oxido de nitrogeno(II); Oxido nitrico; Oxidonitrogen; Oxoazanyl; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd; Stickmonoxyd [German]; Stickstoff(II)-oxid; Stickstoffmonoxid; Vasodilator, Endogenous Nitrate; [NO]; endothelium-derived relaxing factor; monoxido de nitrogeno; monoxyde d'azote; nitric oxide; nitrogen monoxide; nitrogen protoxide; nitrosyl; oxido de nitrogeno(II); oxido nitrico; oxidonitrogen; oxoazanyl; oxyde azotique
Click to Show/Hide
|
||||
| Status |
Phase 2/3
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
NO
|
||||
| InChI |
1S/NO/c1-2
|
||||
| InChIKey |
MWUXSHHQAYIFBG-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
| VARIDT Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Alanine/serine/cysteine/threonine transporter 2 (SLC1A5)
Fat mass and obesity-associated protein (FTO)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Alanine/serine/cysteine/threonine transporter 2 (SLC1A5) is a therapeutic target for Nitric oxide. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Nitric oxide through regulating the expression of Alanine/serine/cysteine/threonine transporter 2 (SLC1A5). | [1], [2] | ||
References